NCT06219902View on ClinicalTrials.gov

A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenHot Flashes
Interventions
DRUG

Elinzanetant (BAY3427080)

Oral administration of multiple doses of elinzanetant.

DRUG

Placebo to elinzanetant

Oral administration

DRUG

Zopiclone

Oral administration

DRUG

Placebo to zopiclone

Oral administration

Trial Locations (1)

H3P 3P1

AltaSciences, Mount Royal

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06219902 - A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women | Biotech Hunter | Biotech Hunter